FOXA1 transcription activates TFF1 to reduce 6-OHDA-induced dopaminergic neuron damage

Tingting Liang1, Ping Zhao1, Xiao Zhang1

  • 1Department of Neurology, The Affiliated Lianyungang Oriental Hospital of Xuzhou Medical University, Lianyungang, Jiangsu 222042, P.R. China.

Insights

Forkhead box A1 (FOXA1) is downregulated in Parkinson's disease (PD). Overexpressing FOXA1 reduces inflammation, oxidative stress, and apoptosis in PD models by activating trefoil factor 1 (TFF1).

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Forkhead box A1 (FOXA1) is crucial in the central nervous system and linked to dopamine synthesis.
  • Downregulation of FOXA1 affects tyrosine hydroxylase, impacting dopamine synthesis and potentially leading to Parkinson's disease (PD).

Purpose of the Study:

  • To investigate the specific role of FOXA1 in Parkinson's disease (PD).
  • To explore the therapeutic potential of FOXA1 in PD treatment.

Main Methods:

  • Examined FOXA1 expression in PD patients' blood via RT-qPCR.
  • Utilized a 6-hydroxydopamine (6-OHDA) induced in vitro PD model using MES23.5 cells.
  • Assessed FOXA1 overexpression effects on inflammation, oxidative stress, and apoptosis using RT-qPCR, assay kits, and TUNEL assays.
  • Investigated FOXA1's downstream mechanism, including binding to the trefoil factor 1 (TFF1) promoter and effects of TFF1 silencing.

Main Results:

  • FOXA1 expression was significantly downregulated in patients with PD.
  • Overexpression of FOXA1 attenuated 6-OHDA-induced inflammation, oxidative stress, and apoptosis in MES23.5 cells.
  • FOXA1 directly binds to the TFF1 promoter, and TFF1 silencing reversed the protective effects of FOXA1 overexpression.
  • FOXA1 activates TFF1 transcription, which in turn alleviates 6-OHDA-induced cellular damage.

Conclusions:

  • FOXA1 plays a protective role in PD by reducing inflammation, oxidative stress, and apoptosis.
  • The mechanism involves FOXA1-mediated transcriptional activation of TFF1.
  • FOXA1 represents a potential therapeutic target for Parkinson's disease.

Related Concept Videos

Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
General Transcription Factors01:30

General Transcription Factors

Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
5.7K
Master Transcription Regulators02:23

Master Transcription Regulators

Master transcription regulators are regulatory proteins that are predominantly responsible for regulating the expression of multiple genes. Often these genes work in concert to drive a  complex process. Activation of a master transcription regulator can lead to a cascade of transcriptional activation necessary for that outcome. These regulators can directly bind to the regulatory sequences of the various genes involved, or they can indirectly regulate transcription by binding to regulatory...
7.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.8K